Antisoma zu alten Höhen ?

Antisoma awarded US Qualifying Therapeutic Discovery Project grant of USD 244K
14:05 08.11.10

London, UK, and Cambridge, MA: 8 November 2010 - Cancer drug developer Antisoma
plc (LSE: ASM; USOTC: ATSMY) today announces that the Company's US subsidiary,
Antisoma, Inc., has received a grant of USD 244,000 under the U.S. Government's
Qualifying Therapeutic Discovery Project, a programme created as part of the
Patient Protection and Affordable Care Act of 2010. The grant is to support the
ongoing development of AS1413 (amonafide L-malate), Antisoma's novel treatment
for acute myeloid leukaemia (AML).

Qualifying Therapeutic Discovery Project grants are awarded to projects that
show a reasonable potential to result in new therapies to treat areas of unmet
medical need or prevent, detect or treat chronic or acute diseases and
conditions, reduce the long-term growth of health care costs in the United
States, or significantly advance the goal of curing cancer within 30 years.

Dr Chris Smyth, VP, Clinical Operations at Antisoma, Inc., said: "We are pleased
that the development of AS1413 has qualified for this recognition, and look
forward to reporting the key phase III data on the drug in the near future."

Enquiries:

Antisoma plc                                   +44 (0)7909 915 068

Glyn Edwards, Chief Executive Officer

Daniel Elger, VP, Marketing & Communications

Buchanan Communications                        +44 (0)20 7466 5000

Mark Court, Jessica Fontaine